About Peroxisome biogenesis factor 10
Peroxisome biogenesis factor 10 (PEX10) is a protein
from Homo sapiens identified by UniProt accession
O60683, 326 residues long.
MolForge cross-references it against 0 known binders and
50 disease associations.
Target properties
| Protein name | Peroxisome biogenesis factor 10 |
| UniProt accession | O60683 |
| Gene | PEX10 |
| Organism | Homo sapiens |
| Length | 326 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (50)
Diseases linked to this target (Open Targets).
- peroxisome biogenesis disorder 6B · score 0.79
- peroxisome biogenesis disorder 6A (Zellweger) · score 0.77
- Zellweger syndrome · score 0.73
- peroxisome biogenesis disorder · score 0.66
- peroxisome biogenesis disorder, complementation group 7 · score 0.65
- Peroxisome biogenesis disorder-Zellweger syndrome spectrum · score 0.57
- Zellweger spectrum disorders · score 0.52
- genetic disorder · score 0.47
- autosomal recessive ataxia due to PEX10 deficiency · score 0.37
- spastic ataxia · score 0.34
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-O60683-F1 | alphafold | PREDICTED | 82.51 | — |
Amino-acid sequence (326 residues)
MAPAAASPPE VIRAAQKDEY YRGGLRSAAG GALHSLAGAR KWLEWRKEVE LLSDVAYFGL TTLAGYQTLG EEYVSIIQVD PSRIHVPSSL RRGVLVTLHA VLPYLLDKAL LPLEQELQAD PDSGRPLQGS LGPGGRGCSG ARRWMRHHTA TLTEQQRRAL LRAVFVLRQG LACLQRLHVA WFYIHGVFYH LAKRLTGITY LRVRSLPGED LRARVSYRLL GVISLLHLVL SMGLQLYGFR QRQRARKEWR LHRGLSHRRA SLEERAVSRN PLCTLCLEER RHPTATPCGH LFCWECITAW CSSKAECPLC REKFPPQKLI YLRHYR
Explore Peroxisome biogenesis factor 10 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets